Finch Therapeutics Group IncChange company Symbol lookupSelect an option...FNCH Finch Therapeutics Group IncRCLFW Rosecliff Acquisition Equity I Warrants Exp 11 Feb 2026 *W EXP 02/11/2026FAST Fastenal CoUKOMW Ucommune International Equity Warrant Exp 17th Nov 2025 *W EXP 11/17/2025KMI Kinder Morgan IncRSG Republic Services IncTGEN Tecogen IncEPAM Epam Systems IncISLE Isleworth Healthcare Acquisition CorpTRMD Torm PLCGo
Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. It is engaged in leveraging its Human-First Discovery platform to develop a class of orally administered biological drugs. Its Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, is an orally administered complete microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection (CDI). CP101, consists of a microbial community harvested from rigorously screened healthy donors that is lyophilized and formulated in orally administered capsules designed to release at the appropriate location in the gastrointestinal tract. CP101 is designed to deliver a complete microbiome, addressing the community-level dysbiosis that characterizes CDI. Its product pipeline includes FIN-211, TAK-524, and FIN-525, as well as consortia product candidates.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| March 31, 2022 | Q4 2021 Earnings Release | -$0.40 | -$0.32 to -$0.32 | -- |
| November 10, 2021 | Q3 2021 Earnings Release | -$0.21 | -$0.42 to -$0.42 | -- |
| August 10, 2021 | Q2 2021 Earnings Release | -$0.32 | -$0.28 to -$0.28 | -- |
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
, , , Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.